A novel Bruton's tyrosine kinase inhibitor JDB175 shows potent efficacy to suppress central nervous system lymphoma

Abstract Patients with central nervous system (CNS) lymphoma face limited treatment options and poor treatment outcomes, emphasizing the urgent need for effective therapeutic strategies. One limiting factor contributing to the suboptimal efficacy is the inadequate penetration of most treatment drugs...

Full description

Bibliographic Details
Main Authors: Yong Xia, Xue Li, Ning Jiang, Xiawei Wei
Format: Article
Language:English
Published: Wiley 2023-12-01
Series:MedComm
Subjects:
Online Access:https://doi.org/10.1002/mco2.424

Similar Items